hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06268522 id: 2023P001582 briefTitle: Adjunctive Mindfulness During Opioid Tapering for patientS With Chronic Pain (The AMOS Study) overallStatus: RECRUITING date: 2024-02 date: 2024-06 date: 2024-06 date: 2024-02-20 date: 2024-02-20 name: Brigham and Women's Hospital class: OTHER briefSummary: This study is a Randomized Controlled Trial exploring the effects of a Mindfulness interventions in reducing pain interference and opioid dose in patients with Chronic Low Back Pain. A total of 200 opioid-using patients with chronic pain, male and female participants will be enrolled, with a need for 160 completers. Patient will be randomly assigned into the Mindfulness-Oriented Recovery Enhancement or the Psychoeducation comparison control group. conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Behavioral primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Mindfulness-Oriented Recovery Enhancement: (MORE) group name: Psychoeducation measure: Pain Interference measure: Opioid Dose measure: Pain Intensity measure: Opioid Misuse measure: Opioid Withdrawal measure: Opioid Craving sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital status: RECRUITING city: Chestnut Hill state: Massachusetts zip: 02467 country: United States name: Marie Curiel role: CONTACT phone: 617-732-9578 email: MCURIEL@mgh.harvard.edu name: Asimina Lazaridou, PhD role: PRINCIPAL_INVESTIGATOR name: Robert Edwards, PhD role: SUB_INVESTIGATOR lat: 42.33065 lon: -71.16616 hasResults: False
nctId: NCT06268509 id: MONAS briefTitle: Nutrition Optimalization Among Pregnant Women to Improve Maternal and Neonatal Outcome in DKI Jakarta acronym: MONAS overallStatus: RECRUITING date: 2023-04-01 date: 2024-06 date: 2024-08 date: 2024-02-20 date: 2024-02-20 name: Dr Cipto Mangunkusumo General Hospital class: OTHER name: Dinas Kesehatan DKI Jakarta name: Fakultas Kedokteran Universitas Indonesia briefSummary: The goal of this MONAS Study is to learn about comprehensive monitoring and nutritional intervention among pregnant women in order to improve maternal and neonatal outcomes. The main questions it aims to answer are:
- All standard maternal health services according to Indonesian Ministry of Health protocol conditions: Pregnancy Complications conditions: Maternal Death conditions: Preeclampsia conditions: Intrauterine Infection conditions: Pregnancy Hemorrhage conditions: Preterm Birth conditions: Neonatal Death conditions: Low; Birthweight, Extremely (999 Grams or Less) conditions: Asphyxia Neonatorum conditions: IUGR studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 245 type: ESTIMATED name: Nutritional panel laboratory examination name: Pregnancy supplements (other than provided by Ministry of Health) name: Fetomaternal ultrasound measure: Composite of poor maternal outcomes measure: Composite of poor neonatal outcomes sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Jakarta Primary Care Health Facility (Puskesmas) under Jakarta Health Office status: RECRUITING city: Jakarta country: Indonesia name: Risal, M.D., M.Sc. role: CONTACT email: dinkes@jakarta.go.id lat: -6.21462 lon: 106.84513 hasResults: False
nctId: NCT06268496 id: LRP23021-A serum briefTitle: Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-02-20 date: 2024-03-05 name: Cosmetique Active International class: INDUSTRY briefSummary: The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo. conditions: Hyperpigmentation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: serum formula 2039125 03 measure: IGA score for patients with melasma or acne induced post-inflammatory hyperpigmentation (PIHP) measure: modified Melasma Area and Severity Index (mMASI) for patients with melasma measure: Post-Acne Hyperpigmentation Index (PAHPI) measure: solar lentigo pigmentation scale measure: colorimetry measurements sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medcin Instituto da Pele Ltda city: Osasco country: Brazil lat: -23.5325 lon: -46.79167 hasResults: False
nctId: NCT06268483 id: JalUrol id: Policlinico type: OTHER domain: IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico briefTitle: Effect of Hyaluronic Acid Oral Supplementation on Sexual and Urinary Symptoms of Women With Recurrent Urinary Tract Infections acronym: JalUrol overallStatus: COMPLETED date: 2022-03-01 date: 2023-03-28 date: 2023-03-28 date: 2024-02-20 date: 2024-02-20 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Uncomplicated urinary tract infections (UTI) are one of the most common bacterial infections globally, causing a significant proportion of medical consultations in primary and outpatient settings. Recurrent UTI (rUTI) have a detrimental impact on the patient's quality of life, causing a negative effect on women's social relationships, self-esteem, as well as irritability and tiredness. Moreover, several real-life studies have shown that reproductive-aged women with rUTI more frequently experience sexual dysfunction as compared to controls without infections. The glycosaminoglycan layer of the bladder urothelium, mainly composed by chondroitin sulfate (CS) and hyaluronic acid (HA), provides a protective barrier against the penetration of bacteria. A deficiency of this layer facilitates bacterial adherence, leading to recurrent infection. Treatment to restore this layer with intravesical instillation of HA has been proven to reduce the incidence of rUTI episodes. Furthermore, intravesical instillation with HA has been associates with sexual function improvement in women with rUTI and painful bladder . Therefore, in conditions where the glycosaminoglycan layer of the bladder is impaired, such as rUTIs, treatment with HA to restore it appears to have a beneficial effect on urinary and sexual symptoms.
Recently, a randomized control trial has demonstrated that an oral formulation of HA, CS, quercetin and curcumin was effective in improving urinary symptoms in women undergoing intravesical chemotherapy for bladder cancer. However, there are no studies investigating the impact of the oral administration of HA and CS on the sexual and urinary symptoms of women with rUTI. Since rUTI are highly prevalent in sexually active women and exert a detrimental impact on women's quality of life, sexual and urinary symptoms, the identification of oral treatments that could alleviate these bothersome consequences is of primary clinical importance.
Inclusion and exclusion criteria We included sexually active, reproductive-aged women with symptomatic rUTIs. Exclusion criteria: younger than 18, if they had used combined hormonal contraception during the previous 6 months; pregnant, breastfeeding or trying to conceive, if they had symptoms of upper UTI, a history of urinary tract anomalies/vesicoureteral reflux, stress urinary incontinence, interstitial cystitis, diabetes, urinary tract stones, neurologic conditions, clinical depression or depressive symptoms.
Statistics: The sample size consisted of 25 participants in each group, calculated by using the two-sample t-test analysis. Baseline clinical and psychometric scores will be compared between I and C groups. Second, potential differences in FSFI values at 3-6 months follow-up assessment will be evaluated between and within groups. Potential predictors of FSFI improvement will be evaluated. conditions: Urinary Tract Infections, Recurrent studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized, crossover primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia name: cranberry, D-mannose, propolis extract, tumeric and Boswellia measure: Improvement in sexual symptoms measure: Improvement in urinary symptoms sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico city: Milan state: MI zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06268470 id: Chula-ARC 001/18 briefTitle: Antiplatelet Therapy in Chronic Urticaria overallStatus: ACTIVE_NOT_RECRUITING date: 2018-06-01 date: 2024-03-01 date: 2024-05-01 date: 2024-02-20 date: 2024-02-21 name: Chulalongkorn University class: OTHER briefSummary: This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria conditions: Chronic Urticaria studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients diagnosed with chronic urticaria will be assigned to 2 treatment arms. 1. high dose antihistamine with antiplatelets; and 2. high dose antihistamine alone. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Identical capsules whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 12 type: ESTIMATED name: Desloratadine plus cilostazol and dipyridamole name: Desloratadine measure: Weekly urticaria activity score measure: D-dimer levels sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine, Chulalongkorn University city: Bangkok zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06268457 id: CE-AVEC 789/2023/Oss/IOR briefTitle: Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis acronym: Embodesmo overallStatus: RECRUITING date: 2024-02-20 date: 2027-02-01 date: 2028-02-01 date: 2024-02-20 date: 2024-03-20 name: Istituto Ortopedico Rizzoli class: OTHER briefSummary: Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive mesenchymal tumors. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.
The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. Embolization of desmoid tumors alone, without chemotherapy, on the contrary, has been shown to be inefficient. Using Doxorubicin in desmoid fibromatosis is effective but associated with systemic toxicity. Consequently, this drug is reserved for symptomatic, nonresponsive, rapidly growing or life-threatening tumors. The intrinsic hypervascularity of desmoid tissue can be exploited as a conduit to achieve local distribution of Doxorubicin by navigation of a catheter endovascular. conditions: Desmoid studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Chemoembolization with Doxorubicin measure: Volume reduction in cm measure: Reduction of pain (VAS score) measure: Reduction of antalgic therapy (mg) measure: Improvement in quality of life (EORTC QLQ-C15-PAL questionnaire) measure: Improvement in quality of life (EORTC QLQ - BM22) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Ortopedico Rizzoli status: RECRUITING city: Bologna state: Emilia Romagna zip: 40136 country: Italy name: Giancarlo Facchini, MD role: CONTACT phone: +39 333 650 0944 email: giancarlo.facchini@ior.it lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06268444 id: PI2023_843_0077 briefTitle: Infant Sleep and Exposure to Mixture of Chemical Environmental Pollutants acronym: SOLANGE overallStatus: RECRUITING date: 2024-02-07 date: 2026-02 date: 2026-02 date: 2024-02-20 date: 2024-02-20 name: Centre Hospitalier Universitaire, Amiens class: OTHER briefSummary: During their first year of life, children spend more than half their time sleeping, a function essential to their neurodevelopment. This period of maturation and development of the future adult is considered extremely vulnerable to environmental exposure. During this period, the child\'s diet is mainly provided by breastfeeding, where persistent chemical substances have been found. A cocktail of 19 mostly persistent substances (POPs) present in breast milk has recently been identified as the main contributor to neurodevelopmental risk. However, the reality of their impact on neurophysiological development, in particular on infant sleep, has yet to be assessed.
In this project, the sleep of children under 6 months of age will be studied using an actimetry watch worn for 7 days by the child, accompanied by a sleep diary. Exposure to environmental pollutants will be assessed by measuring their presence in the infant\'s milk (breastfeeding) and wearing a silicone bracelet to collect air pollutants. A questionnaire on exposure will complement this evaluation. conditions: Newborn conditions: Chemical Pollutants Exposure conditions: Sleep studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 60 type: ESTIMATED name: 7-day actimetry sleep recording name: Determination of environmental pollutants in breast milk name: Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child name: Continuous recording of the child's temperature for 7 days name: Use of a sleep diary for 7 days name: Parental questionnaire of environmental exposure measure: total sleep time per day in infants using actimetry measure: Concentration of various substances in breast milk measure: concentration of chemical polluants on newborn bracelets measure: Child Temperature level (°C) sex: ALL maximumAge: 6 Months stdAges: CHILD facility: CHRU Amiens status: RECRUITING city: Amiens zip: 80054 country: France name: Karen CHARDON, Pr role: CONTACT phone: 03.22.82.78. 65 email: Karen.chardon@u-picardie.fr name: Elodie HARAUX, HARAUX role: PRINCIPAL_INVESTIGATOR name: Pierre TOURNEUX, Pr role: SUB_INVESTIGATOR lat: 49.9 lon: 2.3 hasResults: False
nctId: NCT06268431 id: 43084 briefTitle: Oxytocin Rest to Reduce Cesarean Delivery acronym: ORCA overallStatus: RECRUITING date: 2024-02-15 date: 2026-02-15 date: 2026-03-15 date: 2024-02-20 date: 2024-02-20 name: Christiana Care Health Services class: OTHER briefSummary: Prolonged labor is usually managed with continuous oxytocin infusion. "Oxytocin rest" has been proposed as a strategy to resolve protracted labor in patients who have received continuous oxytocin without progress. This strategy involves discontinuing oxytocin then restarting infusion after a period of time, under the theory that washout of the oxytocin receptor will strengthen uterine contractions to improve labor progress. "Oxytocin rest" is performed on labor and delivery units across the United States. Yet, there is no randomized or prospective data to support the practice.
The purpose of this study is to assess whether oxytocin rest of 60 minutes in patients with prolonged labor reduces risk for cesarean delivery. conditions: Prolonged Labor conditions: Failed Induction conditions: Labor Dystocia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 350 type: ESTIMATED name: Oxytocin rest measure: Cesarean rate measure: Time to delivery (hours) measure: Time to vaginal delivery (hours) measure: Time to active labor (hours) measure: Duration of active labor (hours) measure: Composite maternal adverse outcome measure: Composite neonatal adverse outcome measure: Labor Agentry Scale score measure: Rate of intraamniotic infection (IAI) measure: Rate of postpartum endometritis measure: Rate of postpartum hemorrhage sex: FEMALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: ChristianaCare Health System status: RECRUITING city: Newark state: Delaware zip: 19718 country: United States name: Teresa C Logue role: CONTACT phone: 302-733-6563 email: teresa.logue@christianacare.org lat: 39.68372 lon: -75.74966 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-01-21 uploadDate: 2024-02-11T17:37 filename: Prot_SAP_000.pdf size: 239099 hasResults: False
nctId: NCT06268418 id: 2024PI020 briefTitle: Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy acronym: PADL overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-06-30 date: 2024-08-30 date: 2024-02-20 date: 2024-02-21 name: Central Hospital, Nancy, France class: OTHER briefSummary: Targeted Radionuclide Therapy (TRT) is a contemporary approach to radiation oncology, aiming to deliver the maximal destructive radiation dose via cancer-targeting radiopharmaceutical. Radioactive ligands for the prostate-specific membrane antigen (PSMA) have emerged for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Normal organ and tumor dose can be assessed by a series of cross-sectional whole-body SPECT scans, however, these require a large amount imaging time and are often not feasible in routine clinical practice.
An alternative is to generate a 3D time integrated activity (TIA) map per patient based on the PBPK and the pre-therapy imaging conditions: Radionucleide Therapy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 46 type: ESTIMATED name: Artificial intelligence measure: Evaluate the prediction of the absorbed dose by Deep Learning approaches for RLT with 177Lu-PSMA, from pre-treatment 68Ga-PSMA.PET/CT images measure: Automatically contour the total tumor metabolic volume on 68Ga-PSMA pretreatment PET images using Deep Learning approaches sex: MALE minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06268405 id: 22-5806 briefTitle: Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings overallStatus: RECRUITING date: 2023-09-21 date: 2024-09-21 date: 2024-09-21 date: 2024-02-20 date: 2024-02-20 name: University Health Network, Toronto class: OTHER briefSummary: The goal of this pilot research study is to compare two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to evaluate if findings from Liquid Biopsy can be matched to images obtained by PEM.
Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses an injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion.
If correlations between paired samples are observed between imaging using PEM and the Liquid Biopsy data, further studies will be conducted to evaluate if these techniques can help refine screening investigations and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 30 type: ESTIMATED name: Liquid Biopsy name: Positron Emission Mammography (PEM) measure: Correlation of paired samples between Liquid Biopsy data and Positron Emission Mammography (PEM) images sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network status: RECRUITING city: Toronto state: Ontario zip: M5G 2M9 country: Canada name: Samira Taeb, MSc role: CONTACT phone: 416-946-4501 phoneExt: 5853 email: samira.taeb2@uhn.ca name: Vivianne Freitas role: CONTACT phone: 416-946-2000 phoneExt: 5608 email: vivianne.freitas@uhn.ca name: Vivianne Freitas, MD role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06268392 id: CT-2023-11-20-001 briefTitle: A Comparative Study of AI Methods for Fetal Diagnostic Accuracy in Ultrasound overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2024-08-01 date: 2024-08-01 date: 2024-02-20 date: 2024-02-22 name: Copenhagen Academy for Medical Education and Simulation class: OTHER name: Slagelse Hospital name: Technical University of Denmark name: Rigshospitalet, Denmark briefSummary: This study serves as a supplemental investigation to the randomized controlled SCAN-AID study (NCT0632187). This study will evaluate and compare the fetal growth estimation outcomes of AI-supported groups, expert sonographers, and control groups using a secondary AI predictive model. conditions: Fetal Growth Retardation conditions: Fetal Macrosomia conditions: Fetal Growth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 150 type: ESTIMATED measure: Fetal weight measure: Ultrasound fetal weight estimation sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06268379 id: #08-01-03-23 briefTitle: BMA and Dynamic Nomogram for Survival Prediction in Patients With CRC overallStatus: COMPLETED date: 2010-02-15 date: 2021-12-15 date: 2021-12-15 date: 2024-02-20 date: 2024-02-20 name: Cabrini Health class: OTHER briefSummary: This project will examine the outstanding statistical techniques for predicting the survival of patients with colorectal cancer (CRC) (colorectal neoplasia database). The motivating clinical question that led to proposing this project is based on the general assumption that: "Right-sided colorectal cancer (CRC) has worse survival than left-sided CRC." The question is, which aspects of the patient's characteristics are responsible for this difference? This led us to BMA model selection and provide a clinician-friendly online nomogram. conditions: Colon Cancer conditions: Model Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 2475 type: ACTUAL name: Surgery measure: OS measure: RFS sex: ALL minimumAge: 22 Years maximumAge: 101 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cabrini Health city: Melbourne state: Victoria zip: 3144 country: Australia lat: -37.814 lon: 144.96332 hasResults: False